SUMMARY Increased serum levels of the amino terminal type III procollagen peptide and serum hyaluronan were demonstrated in patients with rheumatoid arthritis. In patients with active disease a significant correlation was shown between serum levels of the propeptide and hyaluronan and the clinical signs of synovitis reflecting the extent of synovial inflammation. During recovery the serum propeptide and serum hyaluronan showed a delayed decline as compared with the clinical signs of synovitis and the acute phase protein response. This probably reflects the presence of persistent subclinical chronic inflammation. Normal serum propeptide levels in rheumatoid arthritis were associated with a good prognosis without progression of erosive joint lesions. Azathioprine reduced the number of patients with progression of erosive joint lesions and caused a more marked suppression of the serum propeptide than levamisole and penicillamine.
disease activity in RA.6 8 The inflamed synovium seems to be the main source of increased S-PIIINP.6 A significant correlation has been shown between the acute phase proteins and S-PIIINP6 and S-HA.8
A preliminary prospective study showed that S-PIIINP may be a useful prognostic marker in RA.6 In the present study the relation between S-PIIINP, S-HA, and the established clinical, biochemical, and radiological variables reflecting synovitis activity was evaluated during a two year, double blind trial of levamisole, penicillamine, and azathioprine in patients with RA." -14 The exclusion criteria were as follows: functional class IV,'7 age of 16 years or less, pregnancy, concurrent diseases with poor life expectancy, clinical sign of abnormal thyroid function, impaired liver function (S-aspartate aminotransferase >40 U/l, S-alkaline phosphatase >275 U/I, and S-bilirubin >17 iimol/l) or kidney function (S-creatinine >120 ,umol/l), patients who refused to participate after receiving information about the trial, and patients who had received levamisole, penicillamine, azathioprine, cyclophosphamide, chloroquine, gold salts, or steroids within the last three months. The study was designed as a two year, double blind trial. Non-responders to treatment were withdrawn from the study after eight months.
Sixty six patients, 45 women and 21 men, aged 31-77 years (median 62 years) with a disease duration of 5-530 months (median 60) were included in the study. Fifty eight patients had erosive disease, and 61 were seropositive (Rose-Waaler test). Sixteen patients had extra-articular manifestations. All had subcutaneous rheumatoid nodules, two had pleurisy, and one polyneuropathy. There was no evidence of disturbed pulmonary function in the remaining patients. Twenty patients allocated to treatment with levamisole were given 50 mg daily for one week, 10() mg daily on the following week, and 150 mg daily as a maintenance dosage. Twenty four patients allocated to penicillamine received 150 mg daily for three weeks. The dosage was raised by increments of 150 mg every three weeks until a dosage of 600 mg daily was reached. Twenty two patients allocated to azathioprine were given 2-5 mg per kilogram body weight daily. All patients were given 1600 mg ibuprofen daily. Other non-steroidal anti-inflammatory drugs were not allowed during the study.
Clinical evaluation of synovitis activity was performed by a 'blind' observer (the same rheumatologist throughout the study) at months 0, 4 2 The analyses were performed as previously described.6 The intra-assay and interassay variations determined with a control reference serum were for the RIA-gnost assay (median 6 5 ng/ml) 5% and 8% respectively, and for the Fab assay (median 53 ng/ml) 5% and 9% respectively. Samples to be compared were run simultaneously, and the values given are means of duplicate determinations. Repetitive thawing, and freezing for up to six years did not influence the S-PIIINP measurements. The higher propeptide levels recorded with the Fab assay are due to a 10-20 times higher affinity of the propeptide degradation product, Col 1, to the antibodies used in the Fab assay, as compared with the antibodies in the RIAgnost technique. 2 Recovery experiments were performed on serum using RIA-gnost and Fab PIIINP assays. The following components were added to 0-25 ml of serum from eight healthy individuals and from eight patients with active seropositive rheumatoid arthritis included in the prospective study: 0-25 ml of phosphate buffer pH 7*2, 0.25 ml purified human propeptide, Col 1-3, in phosphate buffer pH 7*2 (concentration in RIA-gnost assay 15.6 ng/ml, in Fab PIIINP assay 24 ng/ml), or 0-25 ml human Col 1 in phosphate buffer pH 7-2 (concentration in RIAgnost assay 3-9 ng/ml, in Fab PIIINP assay 53 ng/ml). The aliquots were mixed, incubated at 4°C for 16 hours, and analysed. Samples (1-2 ml) were chromatographed by application on a column (1-6x90 cm) of Sephacryl S-300 equilibrated in phosphate buffered saline pH 7-2 containing 0-05% Tween 20, and elution at a flow rate of 14 ml/h. Fractions of 1-9 ml were collected. Each fraction was analysed for the presence of PIIINP immunoreactive material in the RIA-gnost and Fab PIIINP assay. The column was calibrated with labelled intact bovine propeptide, intact human Col 1-3, and human Col 1. The elution volume of the column was determined with dinitrophenylalanine as indicator.
In the prospective study S-PIIINP analyses of one month 0 sample and three month 4 samples were not performed owing to lack of serum.
S-HA was determined by a radioassay for sodium hyaluronate using high affinity binding protein from bovine cartilage according to methods previously described.3 "The intra-assay variation was 12% at a serum concentration of 20 
Results
In healthy control subjects S-PIIINP as measured by the RIA-gnost assay (S-RIA-PIIINP) was 3-2-11-8 ng/ml (median 6.4) and by the Fab assay (S-Fab-PIIINP) 34-85 ng/ml (median 52). The normal level of S-HA was 12-172 ng/ml (median 42).
In serum samples 88-116% (median 99) and 83-104% (median 92) of Col 1-3 added was recovered using the RIA-gnost assay and Fab-PIIINP assay respectively, whereas 77-103% (median 90) and 89-109% (median 98) of Col 1 added was recovered using the RIA-gnost assay and Fab-PIIINP assay respectively. No differences were observed in the recoveries of Col 1-3 or Col 1 between sera from healthy controls or from patients with rheumatoid arthritis. No relation was shown between the recovery percentages of Col 1-3 or Col 1 and the serum concentrations of total IgG, IgM rheumatoid factors, IgG rheumatoid factors, Clq, or circulating immune complexes in the patients with rheumatoid arthritis.
In the prospective study S-RIA-PIIINP, S-Fab-PIIINP, and S-HA levels at months 0, 4, and 8 were significantly higher than in the healthy controls (p<O-OOl) ( Table 1 ). An increase in S-Fab-PIIINP during the first four months was followed by a decrease in S-RIA-PIIINP and S-Fab-PIIINP between months 4 and 8 (Table 1) . S-HA decreased significantly between months 0 and 8 ( Table 1) .
The relation between the pooled observations at months 0, 4, and 8 of S-RIA-PIIINP, S-Fab-PIIINP, and S-HA are shown in Table 2 . A correlation between S-RIA-PIIINP and S-Fab-PIIINP was seen at each observation, whereas the correlation seen at month 0 between S-PIIINP and S-HA disappeared after four and eight months of treatment (Table 3) .
The clinical and paraclinical variables at months 0, 4, and 8 are shown in Table 1 . These indicators of disease activity showed improvement within the first four months, followed by small changes in the same direction during the subsequent four months. No differences were recorded in the clinical signs of disease activity between the three treatment subgroups throughout the study.
Statistically significant correlations were demonstrated between the pooled observations at months 0, 4, and 8 of S-RIA-PIIINP, S-Fab-PIIINP, and S-HA, on the one hand and the tender and swollen joint indices, the grip strength, CRP, ESR, total IgG, and IgG rheumatoid factors, on the other hand ( Table 2) . No statistically significant correlations were observed between the pooled observations of S-RIA-PIIINP, S-Fab-PIIINP, and S-HA, on the one hand and morning stiffness, S-orosomucoid, S-haptoglobin, IgM rheumatoid factors, Clq, and circulating immune complexes, on the other hand.
Statistically significant correlations were observed at month 0 between the S-RIA-PIIINP, S-Fab-PIIINP, and S-HA and the tender and swollen joint indices, and CRP. These correlations disappeared after four and eight months of treatment (Table 3) . No correlations were observed between the connective tissue related serum markers and morning stiffness, grip strength, ESR, S-orosomucoid, Shaptoglobin, total IgG, IgG rheumatoid factors, IgM rheumatoid factors, Clq, and circulating immune complexes at the individual observations at months 0, 4, and 8.
No statistically significant differences were observed in S-RIA-PIIINP, S-Fab-PIIINP, or S-HA between patients with and without extra-articular manifestations. The three patients with extraarticular manifestations other than cutaneous nodules, however, i.e., the two patients with pleurisy and the patient with polyneuropathy, had S-RIA-PIIINP values above 19-7 ng/ml throughout the eight month study.
Fifty four patients completed the first eight months of treatment. The patients were then tNormal range (median): S-RIA-PIIINP 3 2-11-8 ng/ml (6.4 ng/ml). S-Fab-PIIINP 34-85 ng/ml (52 ng/ml), S-hyaluronan 12-172 ng/ml (42 ng/ml). divided into responders and non-responders. Nonresponders (n=30) still fulfilled the inclusion criteria for synovitis activity, whereas the responders (n=24) no longer fulfilled these criteria. One nonresponder was excluded, because the initial serum sample was missing. No differences were found between responders and non-responders in the changes of the serological connective tissue variables within the first four months, whereas a significant reduction of S-RIA-PIIINP was seen in responders as compared with non-responders between months 0 and 8 (responders -15 5 to 8-3 ng/ml (median -2.1), non-responders -9-6 to 15-0 ng/ml (median 1-8); p<0-02), and of S-HA between months 4 and 8 (responders -560 to 379 ng/ml (median -106), non-responders -286 to 400 ng/ml (median -12); p<0.05).
To assess the prognostic value of S-PIIINP and S-HA we calculated the correlations between the initial S-RIA-PIIINP, S-Fab-PIIINP, or S-HA and the clinical synovitis scorings as well as the acute phase proteins at months 4 and 8, and the changes in these variables between months 0 and 8. None of the correlations were significant at a level of p.0-005.
A significant decrease in S-RIA-PIIINP was shown in the 19 patients treated with azathioprine during months 0-8 (-9-6 to 3 4 nglml (median -1-9)) as compared with the change in S-RIA-PIIINP in the 34 patients treated with levamisole or penicillamine during months 0-8 (-16-1 to 15 .0 ng/ml (median 0-2)) (p<0.05). No differences were shown between the levamisole and the penicillamine groups. No differences were seen in the changes in S-Fab-PIIINP and S-HA between the treatment groups.
The relation of S-RIA-PIIINP to treatment, treatment duration, and response is shown in Table  4 . In patients treated with levamisole and penicillamine a significant decrease of S-RIA-PIIINP was seen in responders compared with non-responders, whereas no difference was seen between responders and non-responders treated with azathioprine. The responders showed no changes of S-RIA-PIIINP related to treatment, whereas non-responders to azathioprine treatment had a significant decrease in S-RIA-PIIINP for months 0-4 and 0-8 as compared with the non-responders treated with levamisole or penicillamine. Similar calculations were performed with S-Fab-PIIINP and S-HA, but no relation could be found between these variables and treatment, treatment duration, and response.
There were no significant differences in S-RIA- phase proteins were seen during the first eight months. A small, but significant additional decrease was shown in the swollen and tender joint indices between months 8 and 24, whereas no changes were observed in the acute phase proteins (Table 5) . No statistically significant changes were demonstrated in the serological connective tissue parameters within the first eight months, whereas all three markers showed decreasing levels after two years of treatment (Table 5 ). Only the changes in S-RIA-PIIINP and S-HA were statistically significant, however. No statistically significant correlations were seen between S-RIA-PIIINP, S-Fab-PIIINP, and S-HA and the clinical signs of synovitis or the acute phase proteins after 24 months of treatment.
Serum samples from a woman, age 60, with erosive seropositive classical RA of 13 years' duration were subjected to molecular exclusion chromatography on a Sephacryl S-300 column before and after eight and 24 months of azathioprine treatment. The acute phase reactants normalised within the first four months, whereas the clinical variables and the serological connective tissue metabolites improved throughout the two years of observation (S-RIA-PIIINP, month 0: 23-4 ng/ml, hepatitis.
In the present study S-PIIINP correlated with S-HA only in the initial active phase of synovitis (Table 3 ). S-HA decreased throughout the first eight months, whereas S-PIIINP increased slightly at month 4 followed by a significant decline during the next four months. These changes in circulating matrix elements accord with the temporal pattern of extracellular matrix formation in developing granulation tissue, in which hyaluronic acid dominates in the early stages followed by type III collagen proliferation. 26 32-34 The S-PIIINP antigen profile in active RA and during recovery (Fig. 2) was very similar to that seen during recovery from an episode of alcoholic hepatitis,35 implying that this peptide pattern represents changes which are common to procollagen/ propeptide metabolism during non-specific acute and chronic inflammation: the Col 1-3 fraction dominates in the acute inflammatory phase. The Col 1-3 and the high molecular fraction are prevalent during the chonic inflammatory phase, whereas the Col 1 fraction dominates after complete remission and also in healthy individuals.
The initial S-PIIINP and S-HA were not useful as predictors of the outcome of the clinical or serological variables of inflammation. This finding supports the assumption that the serological connective tissue metabolites reflect alterations in the connective tissue metabolism caused by the inflammatory process, and not factors initiating the inflammation.
In a previous prospective pilot study we Theoretically, the presence of aggregated IgG and rheumatoid factors in serum could interfere directly with the assays, and Clq, which has a collagen-like fragment, could cross react with PIIINP. We only recorded a correlation between S-RIA-PIIINP and total IgG and IgG rheumatoid factors at month 0 (Tables 2 and 3 ). As the recovery of added Col 1-3 or Col 1 was not influenced by the presence of IgG, including IgG rheumatoid factors, this correlation probably indicates that S-RIA-PIIINP, total IgG, and IgG rheumatoid factors are all related to the inflamed synovial mass. The recovery experiments also speak against an influence of circulating anticollagen antibodies on the S-PIIINP levels in RA.36 These antibodies are directed mainly against covalent structural determinants present on denaturated collagens, and, in contrast with S-PIIINP, they show no correlation with disease activity in RA. 36 The present study has confirmed the previously observed suppressive effect of azathioprine on the S-RIA-PIIINP level in active RA. 6 Apparently, this suppression does not represent a non-specific effect on protein synthesis because no differences were observed in serum albumin between the three treatment groups. " 14 The decreased S-PIIINP level in azathioprine non-responders may reflect an azathioprine induced specific suppression of the collagen type III synthesis elicited by acute inflammation. Immunosuppressive treatments leading to declining S-PIIINP values in treatment responders have also been shown in cryptogenic fibrosing alveolitis37 and chronic active hepatitis,38 39 but appear not to influence the S-PIIINP level in primary biliary cirrhosis.4" 4 The importance of suppressing the S-PIIINP level in chronic fibrosing conditions remains to be elucidated. The propeptide, however, seems to be closely related to the pathogenetic processes in the inflamed synovium: RA patients with normal S-RIA-PIIINP have a favourable prognosis as regards progression of joint erosions and there was a minimal progression of joint damage during azathioprine treatment.
